- Previous Close
5.41 - Open
5.49 - Bid 5.17 x --
- Ask 5.20 x --
- Day's Range
5.12 - 5.60 - 52 Week Range
5.12 - 17.32 - Volume
610,300 - Avg. Volume
222,056 - Market Cap (intraday)
785.76M - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
-- - EPS (TTM)
-1.09 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Apr 28, 2020
- 1y Target Est
--
Alliança Saúde e Participações S.A. provides diagnostic medicine services in Brazil. It offers imaging diagnosis and graphic methods; nuclear medicine cytology; pathological anatomy; human vaccination and immunization; medical activity; and clinical analysis, as well as other auxiliary diagnostic support services. The company also engages in the import of medical and hospital equipment, diagnostic sets, and related items; provision of consultancy, advice, courses, and lectures in the health area; managing chronic diseases; research and development in the area of diagnostic medicine; preparation, editing, publication, and distribution of newspapers, books, magazines, periodicals, and other written communication vehicles intended for scientific dissemination; and granting and administration of business franchises. The company was formerly known as Centro de Imagem Diagnósticos S.A. and changed its name to Alliança Saúde e Participações S.A. in April 2023. Alliança Saúde e Participações S.A. was founded in 1992 and is headquartered in São Paulo, Brazil.
www.allianca.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AALR3.SA
View MorePerformance Overview: AALR3.SA
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is IBOVESPA (^BVSP) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AALR3.SA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AALR3.SA
View MoreValuation Measures
Market Cap
823.83M
Enterprise Value
1.63B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.53
Price/Book (mrq)
0.75
Enterprise Value/Revenue
1.34
Enterprise Value/EBITDA
8.82
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.61%
Return on Assets (ttm)
2.54%
Return on Equity (ttm)
-11.27%
Revenue (ttm)
1.22B
Net Income Avi to Common (ttm)
-129.12M
Diluted EPS (ttm)
-1.09
Balance Sheet and Cash Flow
Total Cash (mrq)
114.97M
Total Debt/Equity (mrq)
83.66%
Levered Free Cash Flow (ttm)
-297.98M